Brand Name	:	Labpen 20 mg, 40mg
Generic Name	:	Pentoprazole
Price	:	BDT: 5.00
Therapeutic Class	:	Antiulcerent Products
Section	:	PPI
Dosages	:	The usual recommended adult oral dose is 40 mg given once daily, before breakfast. The duration of therapy is ranging from 2-8 weeks. Duodenal Ulcers: Labpen 40 mg tablet, once daily for 2 to 4 weeks. Duodenal ulcer generally heals within 2 weeks.
Indication	:	Peptic ulcer diseases (PUD), Gastro esophageal reflux diseases (GERD), Treatment of ulcer resistant to H2 receptor antagonists (H2RAs), Treatment of ulcers induced by non-steroidal anti-inflammatory drugs (NSAIDs), Gastrointestinal (GI) bleeding.

Product Details

Composition:

Labpen 20 tablet: Each delayed release tablet contains Pantoprazole Sodium Sesquihydrate USP equivalent to Pantoprazole 20 mg.
Labpen 40 tablet: Each delayed release tablet contains Pantoprazole Sodium Sesquihydrate USP equivalent to Pantoprazole 40 mg.

Description:

Pantoprazole (Labpen) is chemically a novel substituted benzimidazole derivative, which suppresses the final step in gastric acid production by forming a covalent bond to two sites of the H+, K+ - ATPase enzyme system at the secretory surface of the gastric parietal cell. This leads to inhibition of both basal and stimulated gastric acid secretion irrespective of the stimulus. The binding to the H+, K+ - ATPase results in duration of antisecretory effect that persists longer than 24 hours. Pantoprazole (Labpen) is quantitatively absorbed and bioavailability does not change upon multiple dosing. Pantoprazole (Labpen) is extensively metabolized in the liver. Almost 80% of an oral dose is excreted as metabolites in urine; the remainder is found in feces and originates from biliary secretion.

Preparation for Use:
A ready-to-use solution is prepared by injecting 10 mL 0.9% Sodium Chloride Intravenous Infusion into the vial containing the dry powder. The resulting solution should be used within 12 hours and stored at 2-8°C.
After preparation, the solution should be administered over 2 to 15 minutes.

Maintenance therapy:
Maintenance treatment should involve the lowest dose of the drug. Both 20 and 40 mg doses of Pantoprazole (Labpen) are safe and effective in maintaining patients with healed reflux esophagitis and PUD in remission.
Elder patient: No problems with Pantoprazole have been encountered in clinical use in this patient group.

Side Effects:

Potentially life-threatening effects: None has been reported with respect to Pantoprazole.
Severe or irreversible adverse effects: No serious adverse reactions have been described to date.
Symptomatic adverse effects: Headache (1.3%) and diarrhoea (1.5%) are the two commonest reported adverse events. It doesn\'t influence renal, cardiovascular, respiratory, endocrine, cognitive or motor functions and no consistent change have been found in any biochemical or haematological parameters. Peripheral edema has occasionally been reported in female patients. Other side effects may include abdominal pain, dizziness, nausea, epigastric discomfort, flatulence, skin rash, pruritus etc.

Precautions:

Patients should be cautioned that Labpen delayed release tablets should not be split, chewed or crushed.

Use in Pregnancy & Lactation:

Pregnant women: Studies using animals have not found any risk to fetus.
Neonates & Children: No data are available on administration of Pantoprazole.